Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER)
- 26 November 2007
- journal article
- research article
- Published by Elsevier BV in The Lancet Oncology
- Vol. 8 (12), 1079-1087
- https://doi.org/10.1016/s1470-2045(07)70346-7
Abstract
No abstract availableThis publication has 24 references indexed in Scilit:
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsThe Lancet, 2005
- Prognostic Role of a Multigene Reverse Transcriptase-PCR Assay in Patients with Node-Negative Breast Cancer Not Receiving Adjuvant Systemic TherapyClinical Cancer Research, 2005
- Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancerThe Lancet, 2005
- A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast CancerThe New England Journal of Medicine, 2004
- A tool for predicting breast carcinoma mortality in women who do not receive adjuvant therapyCancer, 2004
- A Gene-Expression Signature as a Predictor of Survival in Breast CancerThe New England Journal of Medicine, 2002
- Gene expression profiling predicts clinical outcome of breast cancerNature, 2002
- Polychemotherapy for early breast cancer: an overview of the randomised trialsThe Lancet, 1998
- pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long‐term follow‐upHistopathology, 1991
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu OncogeneScience, 1987